Abstract
Purpose of reviewNeurosteroids have been implicated in the pathophysiology of mood, anxiety, and trauma-related disorders, as well as syndromes specific to women such as premenstrual syndrome, premenstrual dysphoric disorder, postpartum depression, peri- and post-menopausal depression. This review summarizes the role of neurosteroids in the neurobiology of stress and that of pharmaceuticals that modulate neurosteroids in the treatment of these disorders. Recent findingsNeurosteroids may provide novel treatments of mood and anxiety disorders. While endogenous neurosteroids have poor bioavailability, there are other means by which neurosteroid activity may be pharmacologically modulated. Various synthetic neurosteroids are under investigation. In addition, naturally produced exogenous molecules that positively modulate neurosteroid action at GABA A , as well as agents targeting enzymes that degrade or promote synthesis of neurosteroids, are being used to manipulate neurosteroid systems. SummaryNeurosteroids act on a wide variety of neuroreceptors, particularly GABA A , playing roles in both homeostasis and the pathophysiology of stress. There is evidence that many pharmaceuticals used for mood and anxiety disorders including antidepressants, antipsychotics, and mood stabilizers may be effective secondary to their ability to modulate neurosteroids. Synthetic versions of neurosteroids, as well as pharmaceuticals that act indirectly to increase synthesis of neurosteroids, are being studied as possible treatments for a variety of mood and anxiety disorders.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 377-400 |
| Number of pages | 24 |
| Journal | Current Treatment Options in Psychiatry |
| Volume | 5 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 1 2018 |
Fingerprint
Keywords
- Allopregnanolone
- Anxiety
- Depression
- DHEA
- Early life adversity
- Estrogen
- GABA
- Neurosteroid
- Progesterone
ASJC Scopus subject areas
- Clinical Psychology
- Psychiatry and Mental health
Cite this
Neurosteroids in the Pathophysiology and Treatment of Mood and Anxiety Disorders. / Perkins, Elizabeth C.; Newport, Donald J.
In: Current Treatment Options in Psychiatry, Vol. 5, No. 4, 01.12.2018, p. 377-400.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Neurosteroids in the Pathophysiology and Treatment of Mood and Anxiety Disorders
AU - Perkins, Elizabeth C.
AU - Newport, Donald J
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Purpose of reviewNeurosteroids have been implicated in the pathophysiology of mood, anxiety, and trauma-related disorders, as well as syndromes specific to women such as premenstrual syndrome, premenstrual dysphoric disorder, postpartum depression, peri- and post-menopausal depression. This review summarizes the role of neurosteroids in the neurobiology of stress and that of pharmaceuticals that modulate neurosteroids in the treatment of these disorders. Recent findingsNeurosteroids may provide novel treatments of mood and anxiety disorders. While endogenous neurosteroids have poor bioavailability, there are other means by which neurosteroid activity may be pharmacologically modulated. Various synthetic neurosteroids are under investigation. In addition, naturally produced exogenous molecules that positively modulate neurosteroid action at GABA A , as well as agents targeting enzymes that degrade or promote synthesis of neurosteroids, are being used to manipulate neurosteroid systems. SummaryNeurosteroids act on a wide variety of neuroreceptors, particularly GABA A , playing roles in both homeostasis and the pathophysiology of stress. There is evidence that many pharmaceuticals used for mood and anxiety disorders including antidepressants, antipsychotics, and mood stabilizers may be effective secondary to their ability to modulate neurosteroids. Synthetic versions of neurosteroids, as well as pharmaceuticals that act indirectly to increase synthesis of neurosteroids, are being studied as possible treatments for a variety of mood and anxiety disorders.
AB - Purpose of reviewNeurosteroids have been implicated in the pathophysiology of mood, anxiety, and trauma-related disorders, as well as syndromes specific to women such as premenstrual syndrome, premenstrual dysphoric disorder, postpartum depression, peri- and post-menopausal depression. This review summarizes the role of neurosteroids in the neurobiology of stress and that of pharmaceuticals that modulate neurosteroids in the treatment of these disorders. Recent findingsNeurosteroids may provide novel treatments of mood and anxiety disorders. While endogenous neurosteroids have poor bioavailability, there are other means by which neurosteroid activity may be pharmacologically modulated. Various synthetic neurosteroids are under investigation. In addition, naturally produced exogenous molecules that positively modulate neurosteroid action at GABA A , as well as agents targeting enzymes that degrade or promote synthesis of neurosteroids, are being used to manipulate neurosteroid systems. SummaryNeurosteroids act on a wide variety of neuroreceptors, particularly GABA A , playing roles in both homeostasis and the pathophysiology of stress. There is evidence that many pharmaceuticals used for mood and anxiety disorders including antidepressants, antipsychotics, and mood stabilizers may be effective secondary to their ability to modulate neurosteroids. Synthetic versions of neurosteroids, as well as pharmaceuticals that act indirectly to increase synthesis of neurosteroids, are being studied as possible treatments for a variety of mood and anxiety disorders.
KW - Allopregnanolone
KW - Anxiety
KW - Depression
KW - DHEA
KW - Early life adversity
KW - Estrogen
KW - GABA
KW - Neurosteroid
KW - Progesterone
UR - http://www.scopus.com/inward/record.url?scp=85065786794&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065786794&partnerID=8YFLogxK
U2 - 10.1007/s40501-018-0159-8
DO - 10.1007/s40501-018-0159-8
M3 - Review article
AN - SCOPUS:85065786794
VL - 5
SP - 377
EP - 400
JO - Current Treatment Options in Psychiatry
JF - Current Treatment Options in Psychiatry
SN - 2196-3061
IS - 4
ER -